# Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

> **NCT06170970** · PHASE2 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 46 (estimated)

## Conditions studied

- Multiple Sclerosis
- Multiple Sclerosis Fatigue

## Interventions

- **DRUG:** Solriamfetol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06170970
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06170970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06170970, "Solriamfetol for the Treatment of Multiple Sclerosis Fatigue". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06170970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*